Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

182 $(1,591) $ 1,057

Diluted earnings

per common share:

(Loss)/earnings

available to

common shareholders

before cumulative

effect of a change

in accounting

principle $(2.08) $0.12 $(1.04) $0.69

Cumulative effect

of a change in

accounting

principle,

net of tax 7/ - - - 0.02

Diluted (loss)/

earnings per

common share $(2.08) $0.12 $(1.04) $0.71

Average common

shares outstanding

- diluted 1,621 1,497 1,536 1,491

The company incurs substantial costs related to the cholesterol joint venture, such as selling, general and administrative costs, that are not reflected in the "Equity income" and are borne by the overall cost structure of Schering-Plough.

1/ Net sales for the three and twelve months ended December 31, 2007,

both include $626 million of Organon BioSciences (OBS) net sales for

the period November 19, 2007 to December 31, 2007.

2/ Cost of sales for the three and twelve months ended December 31, 2007

both include purchase accounting adjustments of $326 million related

to the acquisition of OBS. Cost of sales for the three and twelve

months ended December 31, 2006 include $45 million and $146 million,

respectively, related to the manufacturing changes announced June 1,

2006.

3/ Research and development for the three and twelve months ended

December 31, 2007 include $21 million and $197 million related to

upfront R&D payments. Research and development for the three and

twelve months ended December 31, 2006 both include $15 million related

to an upfront R&D payment.

4/ Acquired in-process research and development for the three a
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... 6 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,(TSX: PLI) ("ProMetic") ... Phase II trial with PBI-1402 in patients with,chemotherapy-induced anemia ... 18 patients showed an overall statistically significant increase,of the ... and of the hemoglobin,values at week 8. At week ...
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that the Company has ... the appointment of a Vice President of Communications., ... and has been,appointed Executive Director. In addition, Phillip ...
... 1:30 p.m. Eastern Time Today, GAITHERSBURG, Md., March ... financial results and corporate progress for,the full year ended ... we have further demonstrated that Iomai,s,vaccine and immunostimulant patches ... president and chief executive officer,of Iomai. "This lays the ...
Cached Biology Technology:ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 2ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia 3Senetek PLC Announces Appointments of Key Personnel 2Senetek PLC Announces Appointments of Key Personnel 3Iomai Announces Year-End 2007 Financial Results and Business Progress 2Iomai Announces Year-End 2007 Financial Results and Business Progress 3Iomai Announces Year-End 2007 Financial Results and Business Progress 4Iomai Announces Year-End 2007 Financial Results and Business Progress 5Iomai Announces Year-End 2007 Financial Results and Business Progress 6
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society of Human Genetics from October 18 22, ... meant to promote the entry of students, post doctorates ... the basic science community and to encourage the participation ... Genetics. This year MARC conferred 16 awards totaling ...
(Date:8/28/2014)... MD FASEB MARC (Maximizing Access to Research ... for the Genetics Society of America,s 27th Annual ... October 3, 2014 in Pacific Grove, California. ... of students, post doctorates and scientists from underrepresented ... community and to encourage the participation of young ...
(Date:8/28/2014)... Aug. 28, 2014  Privacy Advocate and Senior Staff ... Lynch , joins the lineup of biometric and mobile ... Biometrics UnPlugged Executive Summit in Tampa, Florida ... Previously announced speakers include Steven Rahman, Director, Technology and Strategy ... at Experian. The theme of this year,s event is ...
Breaking Biology News(10 mins):Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... the genome ?those that don't code for proteins ... regulate gene activity. Among those elements are microRNAs, ... expression. , Increasing evidence indicates a role for ... from Children's Hospital Boston now demonstrate that one ...
... Reed Army Institute of Research are developing a method to ... exposed to a bioterrorism agent just by looking at the ... They report their findings today at the ASM Biodefense ... by biological threat agents (BTA) rely upon early diagnosis and ...
... least for mice, it's one that is best made with input ... scientists understand the brain chemicals that guide mate selection, Pfaff and ... mouse alone or a male mouse with a female. The females ... "Our data suggest that female mice may use, or even copy, ...
Cached Biology News:Tiny RNA molecules fine-tune the brain's synapses 2Gene patterns in white blood cells quickly diagnose disease 2When mice choose mates, experience counts 2
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Request Info...
Biology Products: